linjc16/ctgov huggingface dataset:
Out-of Pocket Payments With Lymphedema in France

Study Overview
=================
Brief Summary
-----------------
Lymphedema is a frequent and chronic condition posing a high burden on patients. Clinical guidelines emphasize the role of compression therapy by prescription medical devices. Even in a mandatory publicly funded health insurance system, out-of-pocket payments (OOPP) may exist due to the price and reimbursement setting processes. OOPP may threaten the equity of care and drive patients to forgo care. Our aim was to analyze the distributive effects of OOPP for lymphedema patients in France. A prospective, multicenter study will be conducted in France in 2014 on patients with lymphedema. Household ability to pay will be specified by net income and OOPP will be assessed prospectively over 6 months for outpatient care (visits, drugs, medical devices, nursing care, biological tests, imaging, physiotherapy and transportations). Both mandatory and voluntary health insurance reimbursements will be considered. We will combine concentration curves and concentration indices to assess the distributive effects.

Official Title
-----------------
Out-of Pocket Payments in Patients With Lymphedema in France and Inequities of Access ti Healthcare

Conditions
-----------------
Primary Lymphedema Secondary Lymphedema

Intervention / Treatment
-----------------
* Other: Standard care


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Patient aged over six years, with primary or secondary lymphedema, regardless of the severity of the disease; Patient treated in one of the centres participating in the study; Patient (and her legal representative for minors) who gave her written consent [or did not refuse to participate, according to local Law] ; Patient with Internet access and an active email address. Exclusion criteria: Patients with concomitant chronic venous insufficiency; Patient not covered by any health care insurance scheme; People protected under the law.

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Standard care|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The mean monthly out-of-pocket payment as assessed by an online self-questionnaire |  | 6 months |
Optimization Management Study of Community Urinary Tract Infections Spectrum

Study Overview
=================
Brief Summary
-----------------
Urinary tract infections are the second most common community-acquired infections. Even if extended spectrum β-lactamase-producing Enterobacteriaceae (ESBLE) cause fewer urinary tract infections, their proportion is increasing. New recommendations were published by ANSM in 2015, with specific recommendations for infections due to ESBL-producing Enterobacteriaceae. In this study, we wanted to evaluate the effectiveness of a recall of the 2015 recommendations in the form of a table attached to the ECBU report, associated with hygiene recommendations. Methodology: This prospective, multi-center, non-interventional study was conducted in collaboration with the Labazur laboratory over two 2-month periods, one without modification of the laboratory's practices, the other with the addition of documents on the CBEU report. The primary endpoint was the adequacy of prescriptions to ANSM 2015 recommendations.

Conditions
-----------------
Urinary Tract Infections, Resistant Infection, Community-Acquired Infections, Beta Lactam Resistant Bacterial Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patient who were prescribed by a GP a CBEU during the 2 inclusion periods (from 1/10/2016 to 28/02/2017 with a first period from 01/10/2016 to 30/11/2016 and a second period from 02/01/2016 to 28/02/2017) CBEU analyzed by Labazur laboratory CBEU positive for a spectrum β-lactamase-producing Enterobacteriaceae (ESBLE) Exclusion Criteria: Children Refusal of consent CBEU prescribed by a specialist patient hospitalised for management of the infection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| percentage of adequation to ANSM 2015 guidelines of antibotics prescription for community acquired urinary tract infection before and after CBEU report |  | One month |
Two-staged Approach in Positioning Endobronchial Blockers Without Fiberoptic Guidance

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to find a novel method for placing endobronchial blockers without fiberoptic guidance to provide one-lung isolation during anesthesia for thoracic surgery.

Conditions
-----------------
One-lung Ventilation

Intervention / Treatment
-----------------
* Device: two-staged endobronchial blocker insertion
* Device: single-staged endobronchial blocker insertion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients scheduled for lung resection Exclusion Criteria: refuse to enroll patients with lesions involving mainstem bronchi patients with anomalies in tracheobronchial tree

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: two-staged<br>positioning endobronchial blockers to appropriate bronchus with two-staged methods | Device: two-staged endobronchial blocker insertion<br>* positioning endobronchial blockers in two-staged method<br>Device: single-staged endobronchial blocker insertion<br>* positioning endobronchial blockers in traditional single-staged method<br>|
| Active Comparator: single-staged<br>positioning endobronchial blockers with traditional single-staged methods | Device: two-staged endobronchial blocker insertion<br>* positioning endobronchial blockers in two-staged method<br>Device: single-staged endobronchial blocker insertion<br>* positioning endobronchial blockers in traditional single-staged method<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| location of endobronchial blocker |  | immediately after the insertion of blocker by fiberoptic bronchoscope |
Prevalence of Periodontitis Based Upon Principles Presented by the 2017 Classification: A Hospital-based Cross-sectional Study on a Sample of Young Egyptian Dental Patients

Study Overview
=================
Brief Summary
-----------------
The study aims at determining the Prevalence Of Periodontitis based upon principles presented by the 2017 Classification: A Hospital-Based Cross-Sectional Study on A Sample of Young Egyptian Dental Patients

Official Title
-----------------
Prevalence of Periodontitis Based Upon Principles Presented by the 2017 Classification: A Hospital-based Cross-sectional Study on a Sample of Young Egyptian Dental Patients

Conditions
-----------------
Periodontitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients whose age from 12 to 39 years old . Patient consulting in the outpatient clinic Provide informed consent. Exclusion Criteria: Patients having problem in opening their mouth or undergoing inter maxillary fixation where oral examination will not be possible. Patients diagnosed with psychiatric problems or intoxicated with alcohol or drugs

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 39 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Probing pocket depth Staging & Grading | UNC-15 periodontal probe | up to 1 day | 
| Clinical attachment level | UNC-15 periodontal probe | up to 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Nutritional status | Questionnaire Yes-No | up to 1 day |
CPC in Adult Refractory Glaucoma

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the relative effectiveness and safety of diode laser cyclophotocoagulation procedure to reduce IOP and relieve pain in adult patients with refractory glaucoma.

Detailed Description
-----------------
A hospital -based, prospective interventional non comparative case series study.This study will be conducted on patients with refractory glaucoma whose ages are 18 years and older.They will be subjected to Transscleral Diode Laser Cyclophotocoagulation. Postoperative evaluation will be scheduled for the first day postoperative, then 1 week later and then at 1st, 3rd, month postoperative.

Official Title
-----------------
Evaluation of Diode Laser Cyclophotocoagulation in Adult Refractory Glaucoma

Conditions
-----------------
Refractory Glaucoma

Intervention / Treatment
-----------------
* Procedure: Diode Laser Cyclophotocoagulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Inclusion Criteria: Patients with refractory glaucoma aging 18 years and older. Both sexes are included. Patients Capable of giving informed consent. Pseudophkic glaucoma. Aphakic glaucoma. Silicon oil induced glaucoma. Neovascular glaucoma. Inflammatory glaucoma. Exclusion Criteria: Patients <18 years of age. Patients controlled on regular antiglaucomatous therapy. Patients who cannot do regular follow up visits. Diffuse scleral staphyloma at the site of CPC.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Refractory glaucoma<br> | Procedure: Diode Laser Cyclophotocoagulation<br>* A handpiece (G probe) is used to deliver the diode laser energy with a wavelength of 810 nm.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in intraocular pressure | IOP measuring using Goldmann applanation tonometer. | First day postoperative and 1 week |
Biomarkerscreening in Cervical Cancer and Its Preinvasive Lesions

Study Overview
=================
Brief Summary
-----------------
The following trial is a multicenter and prospective research trial of the colposcopy unit of luebeck university and the national research center in Borstel, Germany. The study is to identify and evaluate new biomarkers in human papilloma virus (HPV) associated malignancies and its preinvasive lesions of the cervix uteri. Fresh tissue samples being removed during conizations and/or hysterectomies are to be fixed in HOPE's solution and analyzed according to their transcriptomes and methylosome. The hereby found candidates are to be validated using immunohistochemistry and RT [real-time] -PCR [polymerase chain reaction]. The project is meant to be followed by continuous studies developing a new test describing the malignant potential of HPV associated genital lesions.

Official Title
-----------------
Biomarkerscreening Via Transcriptome and Methylosome Analysis in Cervical Cancer and Its Preinvasive Lesions

Conditions
-----------------
Evaluation of New Tissue Biomarkers for Cervical Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Positive informed consent Patients with suspected preinvasive genital lesion Patients with confirmed genital lesion (both preinvasive and invasive) Contact via dept. of obs/gyn of luebeck university Complete set of data Exclusion Criteria: Incomplete set of data Negative informed consent
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CIN III (cervical intraepithelial neoplasia) lesions | number of CIN III lesions | three years | 
| cervical cancer | number of cervical cancer probes | three years | 
| HPV | number and type of HPV infection of the analyzed probes | three years |
S-Adenosylmethionine Therapy for Non-Alcoholic Steatohepatitis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to examine the effect of S-adenosylmethionine therapy in those patients with non-alcoholic liver disease in the form of steatohepatitis (NASH). This will be accomplished by development of a database of these patients, all of whom will have biopsy documented NASH. A placebo controlled trial will then examine the effect of S-adenosylmethionine over time on clinical outcome in these patients. It is expected that this agent will slow or halt the progression of this disease.

Official Title
-----------------
S-Adenosylmethionine Therapy for Non-Alcoholic Steatohepatitis

Conditions
-----------------
Hepatitis

Intervention / Treatment
-----------------
* Drug: S-adenosylmethionine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men with biopsy proven non-alcoholic steatohepatitis from the liver disease clinic or referred from other physicians from the VAMC-Louisville.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: S-adenosylmethionine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
s-adenosylmethionine, fatty liver, obesity, Non-alcoholic steatohepatitis
The Value of VOCs Analysis in Exhaled Breath for Pulmonary Benign and Malignant Lesion Diagnosis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to analysis the volatile organic gases(VOCs) in exhaled breath of pulmonary lesion patients and healthy controls, in order to find the difference of composition and concentration among groups.

Detailed Description
-----------------
Collect the exhaled gas in pulmonary lesion patients and healthy controls, using proton transfer reaction mass spectrometry to analysis the different composition and concentration of VOCs, to find the biomarker gases of distinguishing benign and malignant lesion of lung among different groups， and try to build a diagnostic model for lung lesion.

Official Title
-----------------
The Value of VOCs Analysis in Exhaled Breath for Pulmonary Benign and Malignant Lesion Diagnosis

Conditions
-----------------
Lung Neoplasm, Lung Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: cohort 1 : Inclusion criteria: Patients newly diagnosed with primary lung cancer by tissue biopsy and did not receive any treatment aiming at the tumor, including chemotherapy and radiotherapy. Age ≥ 18 years cohort 2： Inclusion criteria： Patients diagnosed with pulmonary benign lesion by tissue biopsy or other examination. Age ≥ 18 years Exclusion Criteria: patients who have more than one type of carcinoma patients diagnosed type 2 diabetes mellitus patients diagnosed chronic renal failure patients diagnosed upper digestive tract ulcer patients who reject to sign the informed consent from cohort 3： Healthy controls Volunteers without diagnosed lung diseases and pulmonary symptoms.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Primary lung cancer<br>patients newly diagnosed with lung cancer by tissue biopsy and did not receive any treatment aiming at the tumor, including chemotherapy and radiotherapy. | |
| Benign lung lesion<br>Patients diagnosed with pulmonary benign diseases. | |
| Healthy control<br>Patients without any pulmonary abnormal symptoms or diseases | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mass-to-charge Ratio | It is the measurement result of VOCs in exhaled breath using PTR-MS device. | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pulmonary lesion, Volatile Organic Compositions(VOCs)
Post Marketing Surveillance of Alesion® in Japanese Paediatric Patients With Allergic Rhinitis, Eczema/Dermatitis, Urticaria and Pruritus

Study Overview
=================
Brief Summary
-----------------
Study to investigate the safety and efficacy of Alesion® Dry Syrup under the proper use in daily clinical practice in Japanese paediatric patients with allergic rhinitis, eczema/dermatitis, urticaria and pruritus

Official Title
-----------------
Post Marketing Surveillance of Alesion® (Epinastine Hydrochloride) Dry Syrup -Drug Use-Results Survey of Alesion® Dry Syrup-

Conditions
-----------------
Rhinitis, Allergic, Perennial

Intervention / Treatment
-----------------
* Drug: Alesion®


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All the patients who: haven't treatment experience of epinastine product; have at least one out of following diseases. allergic rhinitis, eczema, dermatitis, pruritus, urticaria Exclusion Criteria: Alesion® Dry Syrup is contraindicated for the patients with history of hypersensitivity to any ingredients of Alesion® Dry Syrup in package insert. However, it was unknown whether a patient was hypersensitive to the ingredients of the product in almost cases. And this survey was drug utilization study to observe actual use in any patients. Therefore exclusion criteria are not set in the protocol
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with allergic rhinitis, eczema/dermatitis, urticaria<br> | Drug: Alesion®<br>* Dry Syrup<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of adverse drug reactions | classified by Medical Dictionary for Regulatory Activities (MedDRA) terminology | up to 3 years | 
| Incidence of adverse drug reactions classified by patient's background/treatment factors |  | up to 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall assessment of efficacy by investigator on a 3-point scale |  | At 12 weeks and 52 weeks |
Screening for Inherited Heart Disease

Study Overview
=================
Brief Summary
-----------------
Genetically inherited heart diseases like hypertrophic cardiomyopathy (HCM) are conditions affecting the heart passed on to family members by abnormalities in genetic information. These conditions are responsible for many heart related deaths and illnesses. Presently, there are several research studies being conducted in order to improve the understanding of disease processes and symptoms associated with genetically inherited heart diseases. This study is designed to determine the eligibility of patients diagnosed with or suspected to have inherited heart disease to participate in these research studies.

Detailed Description
-----------------
Patients with hypertrophic cardiomyopathy (HCM) and other inherited cardiac diseases are being studied under several research protocols to determine their pathogenesis and clinical manifestations. The purpose of this protocol is to determine the eligibility of patients with known or suspected inherited heart conditions for our research protocols.

Official Title
-----------------
Evaluation of Patients With Known or Suspected Inherited Heart Disease (Screening Protocol)

Conditions
-----------------
Heart Disease, Hypertrophic Cardiomyopathy

Participation Criteria
=================
Eligibility Criteria
-----------------
INCLUSION CRITERIA Subjects and family members known or suspected to have inherited a cardiac disease such as HCM. EXCLUSION CRITERIA Patients with cardiac conditions that are not known to be inherited.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hypertrophic Cardiomyopathy, HCM, Evaluation for Research, Medical Advice